Drug Type Non-degrading molecular glue |
Synonyms RMC 4550, RMC4550 |
Target |
Action inhibitors |
Mechanism SHP2 inhibitors(Src homology phosphotyrosyl phosphatase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H26Cl2N4O2 |
InChIKeyIKUYEYLZXGGCRD-ORAYPTAESA-N |
CAS Registry2172651-73-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS Mutant Pancreatic Cancer | Preclinical | Germany | 01 Nov 2022 | |
Acute Myeloid Leukemia | Preclinical | United States | - | |
Esophageal Carcinoma | Preclinical | United States | - |